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Chimeric Antigen Receptor (CAR) redirected T cells are a potent treatment option for certain 
hematological malignancies. Recently, site-specific insertion of CARs into the T cell receptor 
(TCR) alpha constant (TRAC) locus using gene editing and adeno-associated viruses was 
shown to generate CAR T cells with improved functionality over their retrovirally transduced 
counterparts. However, the development of viruses for gene transfer is complex and 
associated with extensive costs at early clinical stages. Here, we provide an economical and 
virus-free method for efficient CAR insertion into the TRAC locus of primary human T cells 
via CRISPR-Cas mediated homology-directed repair (HDR). While the toxicity induced by 
transfected double-stranded template (donor) DNA was not fully prevented by 
pharmacological means, the combination of DNA-sensor inhibitors and HDR enhancers 
resulted in highly efficient gene editing with TCR-to-CAR replacement rates reaching up to 
68%. The resulting TCR-deficient CAR T cells show antigen-specific cytotoxicity and 
cytokine production in vitro. Our GMP-compatible non-viral platform technology lays the 
foundation for clinical trials and fast-track generation of novel CAR T cells applicable for 
autologous or allogeneic off-the-shelf use.  
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Chimeric Antigen Receptor (CAR) redirected T cells are a potent treatment option for certain 
hematological malignancies, such as relapsed acute B-cell leukemia and aggressive B-cell 
lymphoma1,2. Clinical studies have shown CAR T cell efficacy in patients with treatment 
refractory multiple myeloma3,4. Furthermore, CAR T cell therapy is under development for 
solid tumors5,6. Their potential has been expanded to other disease entities and they have 
shown preclinical evidence in liver and cardiac fibrosis7,8, in autoimmune diseases 9,10 and in 
the prevention and treatment of allogeneic immune responses via CAR-reprogrammed 
regulatory T cells in transplantation medicine11,12.   
Lenti- and retroviral gene transfer are the current gold standards for clinical manufacturing of 
CAR T cells. High expression levels after random transgene integration are achieved by the 
use of strong viral promoters. Excessive CAR expression, however, may contribute to tonic 
signaling and potentiate T cell susceptibility to activation induced cell death13,14 and 
exhaustion15. Furthermore, virus production is a laborious procedure requiring regulatory 
approval for preclinical research in many countries. Moreover, the costs associated with the 
production of clinical grade retroviruses are a limiting factor for the translation of new CAR T 
cell therapies16. 
Preclinical evidence suggests that targeted integration of CAR transgenes into the T cell 
receptor (TCR) alpha constant chain (TRAC) gene locus allows for optimally regulated 
expression and superior functionality through reduced T cell exhaustion in vitro and in 
vivo15,17. Additionally, resulting TRAC-integrated and thus TCR/CD3-deficient CAR T cells 
avoid the risk of hazardous allogeneic graft-versus-host disease and offers a potential route 
towards off-the-shelf products after purification of TCR-negative CAR-T cells18. Furthermore, 
site-specific insertion of CAR transgenes using genome-editing techniques reduces the risk 
of insertional mutagenesis which can occur through retroviral gene transfer and it can avoid 
CAR expression in contaminating leukemia cells19. 
TRAC-integration of CAR expression-modules has been achieved through nuclease-
assisted homology directed repair (HDR)15,17. In previous studies,  Streptococcus pyogenes 
(Sp)Cas9-single guide (sg)RNA ribonucleoprotein (RNP) complexes were transfected into 
anti-CD3/CD28-stimulated T cells followed by transduction with recombinant adeno-
associated virus serotype 6 (rAAV6) for HDR donor template (HDRT) delivery15,17. Other 
nucleases have also been used in this context to induce DNA double stand breaks to initiate 
HDR20,21. While RNP-based gene editing is commonly used to modify T cells22 and 
retrovirally-transduced CAR T cells23,24, few research publications have reported the use of T 
cells with CARs integrated at the TRAC locus15,17,20,21,25,26. The aforementioned studies have 
used methods requiring high titers of rAAV6 for donor delivery, thus necessitating virological 
expertise and labor-intensive production even at preclinical scale. Therefore,  we conclude 
that there is a need for methods that circumvent the practical hurdles of virus production. 
Non-viral reprogramming is an attractive alternative to the conventional approaches which 
circumvents the need of rAAV6 for effective donor DNA delivery15,27. Roth et al. achieved 
efficient site-specific transgene insertions by co-electroporation of CRISPR-Cas RNPs and 
single or double stranded DNA (dsDNA) HDR templates28. Small fluorescent tags (~700 
base pairs [bp]) were efficiently integrated into different genetic loci in primary human T 
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cells28. However, this approach is less efficient when delivering therapeutically relevant 
transgenes for adoptive T cell transfer with lengths exceeding 1500 bp28. Integration rates of 
tumor-specific TCRs range from 5% (∼2100 bp insert)29  to 15% (1545 bp insert)28,30. Even 
under optimized conditions, significant cell toxicity of up to 70-80% still occurs31. To date, 
virus-free gene editing has not been used to introduce CAR transgenes into the TRAC gene 
locus.  
The toxicity of non-viral reprogramming in T cells is likely dependent on 2 major factors: The 
first is the physical strain of co-electroporation of dsDNA and RNP aggregates into cells. 
This issue has been partially addressed by the use of anionic polymers such as Poly-L-
glutamic acid (PGA), which was recently shown to improve knock-in rates and reduce 
toxicity by physically dispersing large RNP aggregates into smaller complexes32. 
Additionally, Nguyen and colleagues suggested a modification of HDR-donor DNA using 
truncated Cas9 target sequences (tCTS) flanking both homology arms (HAs). The tCTS 
create binding sites for the co-delivered RNPs. The bound RNPs shuttle the DNA into the 
cell nucleus via the nuclear localization sequences (NLS) of the SpCas9 nuclease, leading to 
improved knock-in rates, however, it also increases toxicity when higher amounts of tCTS-
modified donors are used32. The second major factor in the toxicity of non-viral 
reprogramming of T cells are the endogenous immune responses triggered by cytosolic 
dsDNA mediated by innate DNA-sensor protein pathways33 such as cyclic GMP-AMP 
synthase (cGAS), which is activated in a DNA length dependent manner34 promoting 
apoptosis via its downstream signaling effector stimulator of interferon genes (STING)35. To 
the best of our knowledge, interference with DNA-sensing has not been investigated to 
modulate gene editing outcomes in human T cells. 
In this study, we provide a guide to fast and efficient virus-free integration of CARs into the 
TRAC locus of primary human T cells using an optimized method adapted from prior 
works28,32. We hypothesized that cell viability is primarily compromised by toxicity of dsDNA 
donor templates. We therefore assessed if temporary inhibition of cytosolic DNA-sensors 
increases the viability and CAR insertion rates after DNA transfection. Additionally, we 
investigated whether HDR-enhancing substances could amplify HDR integration rates with 
low amounts of dsDNA donors and different nucleases. Finally, we show that transient 
dsDNA-sensor inhibition synergizes with two commercially available HDR enhancers for 
effective CAR T cell generation. In vitro assays provide proof-of-principle for the functionality 
of CD19- and BCMA-specific CAR T cells generated under optimized conditions for TRAC 
integration.  
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Nuclease selection to insert a CD19-specific CAR via CRISPR-Cas9 assisted HDR 
 
In order to perform optimization experiments with a clinically relevant transgene, we 
rationally designed a second generation CD19-specific CAR with an intermediate length 
IgG1 hinge for detection purposes, a CD28 costimulatory domain followed by the CD3 zeta 
effector chain (Fig. 1 a, Suppl. table 1). We chose the sgRNA targeting TRAC exon 1 with 
the fewest in silico predicted off-targets for our experiments21, since careful selection of 
gRNAs is required to avoid off-targets and to ensure a high level of safety for future clinical 
translation36. We modified the 5’ end of the sgRNA spacer sequence to further decrease the 
risk for off-target editing (here: 5’- GGGAATCAAAATCGGTGAAT-3’ instead of 5’- 
GAGAATCAAAATCGGTGAAT-3’). Empirical nomination of off-target activity using GUIDE-
seq indicated 5 potential off-target sites for the original sgRNA, and identified only 1 off-
target event for our target sequence modified sgRNA (Suppl. Fig. 1). To insert a 2015 bp-
sized CAR transgene in frame with TRAC exon 1, we created a donor template for HDR 
(Fig. 1a, DNA- and amino acid sequences disclosed in Suppl. table 1). The insert was 
flanked with symmetric homology arms (HA) (400 bp each) consisting of a P2A-self-
cleavage site, the CD19-CAR cDNA and a bovine growth hormone (bGH) derived 
polyadenylation sequence (pA). Two types of HDRT were prepared as previously described: 
one with regular HAs (reg. HA) and one with tCTS-modified HAs (tCTS-HA)32 (Suppl. table 
1). 
 
Optimization of transfection conditions and pre-electroporation culture of T cells 
 
First, we re-evaluated multiple parameters of the original protocols28,32 to generate an 
optimized version with increased cost-efficacy by substituting or reducing expensive 
reagents. In line with previous reports, 1x106 activated primary human T cells per 20 µl 
electroporation solution were optimal for cell survival and knock-in rates (Suppl. Fig. 2 a). 
We found that the amount of Cas9 protein could be reduced from 10 to 4 µg / 
Electroporation (E’) without decreasing knock-in or knock-out efficiencies as determined by 
flow cytometry (Suppl. Fig. 2 b). Furthermore, we confirmed the positive effects of PGA on 
cell survival and relative CAR insertion rates for both dsDNA donor formats (regular HA and 
tCTS-HA) (Suppl. Fig. 2 c). When HDR donor templates were transfected without RNPs, no 
transgene expression was detectable by flow cytometry two days after electroporation 
(Suppl. Fig. 2 d). T cell stimulation with plate-bound anti-CD3/CD28 antibodies resulted in 
29% (range: 27-41%) higher CAR+ T cell yield compared to anti-CD3/CD28-coated T cell 
activator beads28,32, without affecting insertion rates determined at day 7 post electroporation 
(Suppl. Fig. 2 e). The commercial P3 primary cell nucleofection buffer could be substituted 
with a self-made electroporation solution “1M”37 albeit leading to 2-5 %-points lower knock-in 
rates (Suppl. Fig. 2 e). 
 
Cell toxicity is dependent on the amount of transfected dsDNA donor templates 
 
Using our optimized protocol (T cell stimulation in anti-CD3/CD28-coated wells, cell count: 
1x 106 / E’, amount of Cas9: 4 µg / E’, volume PGA: 0.5 µl / E’, buffer 1M), we investigated 
the effects of dsDNA HDR donor dosage and format as well as different pharmacological 
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interventions on gene insertion rates and cell survival two days after transfection. In contrast 
to previous results32, we detected significant dose-dependent toxicity with regular HA dsDNA 
donors (Fig. 1 b-e). As expected, this trend was more pronounced with tCTS donor 
templates likely owing to enhanced DNA delivery as observed previously32. Mean toxicity at 
the highest HDRT amount tested (regular HA: 4 µg, tCTS: 2.5 µg) was 87% for regular HA 
and 90% for tCTS-HA, compared to mock-electroporated controls (Fig. 1 d, e). Generally, 
we observed moderate donor variability regarding DNA toxicity (Fig. 1 e). Within 48 hours, 
an average of 20% and 24% of living cells showed CAR surface expression after delivery of 
0.5 µg HDRTs with regular HA and tCTS-HA, respectively (Fig. 1 d, e). Application of tCTS 
HDRTs tended towards increased CAR T cell counts at the lowest HDRT amount. In the 
resulting population of CD3-negative T cells, we observed an increase in relative CAR 
knock-in rates, up to 35% for regular HA and 42% with tCTS-HA at the respective highest 
amount of DNA used. However, overall CD3 knock-out rates decreased when using large 
HDRT amounts, indicating inhibitory DNA-RNP interaction with both HDRT-formats (Fig. 1 
e). Cytokine analysis of cell culture supernatants collected 24 hours after transfection 
revealed dose-dependent release of IL-6 and TNFα, two cytokines that have been 
associated with intracellular sensing of dsDNA33 (Fig. 1 f, g). In contrast, IL-1β was barely 
above the minimal detection level and without a clear trend, indicating minimal AIM2-
mediated inflammasome activation in T cells (Fig. 1 f, g). Taken together, dsDNA HDRT 
amounts exceeding 0.5 µg decreased CAR T cell yield through increased toxicity and 
reduced knock-out efficiency despite slightly increasing CAR knock-in rates at higher HDRT 
concentrations.  
 
Different DNA-sensor inhibitors can impact cell viability or CAR-integration rates 
 
Transfected dsDNA activates innate immune pathways within T cells, thereby contributing to 
a loss in viability after electroporation of large dsDNA HDRT34,35 (Fig. 1). Aiming to improve 
T cell viability, we investigated whether temporary inhibition of intracellular dsDNA-sensors 
or associated downstream pathways could increase the survival of transfected T cells. 
Accordingly, we tested the effects of treating T cells before and/or after electroporation with 
one of the following compounds: 1. ODN A151, a modified DNA oligonucleotide, resembling 
the telomere repeat quadruplex 5’-TTAGGG-3’, which blocks endosomal Toll-like receptor 9 
(TLR9) as well as other cytosolic DNA-sensors (cGAS, AIM2); 2. Ru.521, a small molecule 
antagonist of cGAS; 3. H151, a small molecule inhibiting STING; and 4. BX795, a small 
molecule that prevents activation of Tbx1, a kinase downstream of STING (Fig. 2 a, b). Cell 
viability after transfection of 2.0 µg of tCTS-modified HDRT was partially rescued by 6 hours 
pre-treatment with ODN A151 and BX795 (Fig. 2 c), but this effect was not observed with 
1.0 µg reg. HA HDRT (Fig. 2 d). Extended presence of BX795 and RU.521, especially after 
electroporation, lead to minimal T cell recovery, indicating toxicity of continued exposure to 
these compounds. Strikingly, pre-treatment with the cGAS-inhibitor RU.521 appeared to 
increase the relative CAR insertion rate (Fig. 2 c, d).  
 
Treating T cells with two DNA-sensor inhibitors prior to electroporation improves CAR T cell 
generation at low dsDNA dose 
 
Consequently, we evaluated whether a combined pre-treatment with ODN A151 and RU.521 
could increase TCR-to-CAR replacement rates while retaining high T cell recovery with 
escalating amounts of reg. HA HDRT. (Fig. 2 e, f). We observed a small but consistent 
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increase in the relative CAR expression rate as well as an increase in the absolute CAR T 
cell recovery at the lowest HDRT concentration (Fig. 2 f). Supernatant analysis revealed 
moderate suppression of IL-6 release by combined DNA-sensor inhibition, but no effects on 
TNFα and IL-1β, indicating an incomplete block in cytosolic dsDNA sensing. When 
transfection was performed with anti-CD3/CD28-stimulated peripheral blood mononuclear 
cells (PBMC), DNA-sensor inhibition reduced IL-1β production, which may be related to 
residual B cells and monocytes in the starting population (data not shown). Surprisingly, we 
saw a DNA-independent effect of DNA-sensor inhibition on Th2-associated cytokines IL-10 
and IL-13 (Fig. 2 g), suggesting differential sensitivity of various T helper pathways.  As cell 
cycle is a key determinant of DNA repair outcome38, we explored the effects of our drug 
combination on cell cycling prior to transfection as previously described39. Flow cytometric 
evaluation revealed an increased proportion of T cells within S-phase after 6 hours of pre-
treatment with ODN A151 and RU.521 (Suppl. Fig. 3), which may explain the small increase 
in relative TCR-to-CAR replacement (Fig. 2 f). As DNA toxicity was not effectively prevented 
through transient DNA-sensor inhibition, we conclude that low dsDNA amounts (0.5 - max. 
1.0 µg HDRT) are superior for effective CAR T cell generation (Fig. 1e, 2f). 
 
HDR-enhancers increase relative CAR-insertion rates in primary human T cells 
 
Pharmacologic intervention in DNA repair processes represents an alternative strategy to 
obtain higher HDR rates as previously demonstrated for other gene editing procedures40,41. 
Therefore, we evaluated whether two commercially available HDR enhancing compounds 
(Alt-R HDR enhancer Version 1 [V1] and Alt-R HDR enhancer Version 2 [V2]) would 
increase the relative TCR-to-CAR replacement rate in our protocol (Fig. 3 a). We found a 
dose-dependent increase in the relative CAR insertion rate to 38% with V1 (range: 28-44%) 
and 43% with V2 (range: 31-53%) at their highest respective dose two days after 
electroporation (Fig 3 b, c). Due to the toxicity observed in some donors at the highest dose, 
we chose V1 at a concentration of 15 µM for subsequent experiments. The increase of CAR 
insertion mediated by use of HDR enhancer V1 was reproduced with another TRAC-HDR 
template28 and was increased irrespective of the chosen nuclease and sgRNA (Fig. 3 d, e). 
Suboptimal gene editing with an engineered Cas12a molecule from Acidaminococcus 
species (Alt-R A.s. Cas12a (Cpf1) Ultra, [Ultra-AsCpf1])42 as well as the HiFi SpCas943 could 
be increased by the HDR enhancer V1 (Fig. 3 d, e, f).  
 
Timing and temperature affects HDR modulation during virus-free CAR insertion in T cells 
 
As gene editing with RNPs is likely to happen immediately after transfection44–46, we 
evaluated timing and cell culture conditions and their effects on pharmacologic modulation of 
CAR integration with HDR enhancers. HDR enhancers showed reduced effects when the 
supplemented medium was not pre-warmed, indicating their temperature-dependent activity 
(Suppl. Fig. 4 a). Of note, extended time between electroporation and transfer into HDR 
enhancer containing medium decreased the desired effects (Suppl. Fig. 4 b). Exposing T 
cells to HDR enhancers longer than the first three hours after transfection did not improve 
CAR integration rates (Suppl. Fig. 4 c). Both HDR enhancers improved CAR insertion (Fig. 
3 f) and TCR/CD3 knock-out rates with HiFi SpCas9 in a dose-dependent manner (Suppl. 
Fig. 4 d, e). These results indicate that HDR enhancers can potently increase HDR-
mediated CAR integration into the TRAC gene in primary human T cells. 
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Transient DNA-sensor inhibition synergizes with HDR enhancers for efficient generation of 
TRAC-replaced CAR T cells 
We subsequently tested whether the combination of DNA-sensor inhibition (ODN A151, 
Ru.521) and HDR enhancers could increase the absolute CAR T cell yield at 2 and 7 days 
after transfection  (Fig. 4 a). We observed a synergistic effect on the relative TCR-to-CAR 
replacement rate as well as an increase in absolute CAR T cell recovery (Fig. 4 b). The 
increase in relative CAR insertion rates was independent of the donor template HA format 
(Fig. 4 b). In general, higher knock-in rates and improved CAR T cell yields were achieved 
when CD3-enriched T cells, instead of unselected PBMC, were used as a starting population 
(Suppl. Fig. 5 a). Synergy between DNA-sensor inhibition and HDR enhancer V1 was also 
observed after transfection of larger HDRT amounts, although the CAR T cell yield remained 
smaller than with optimized low dsDNA concentrations (Suppl. Fig. 5 b). In a further 
experiment using 1.0 µg reg. HA HDRT, temporary dsDNA-sensor inhibition further 
increased CAR integration rates with both HDR enhancers at all tested dosages, enhancing 
the CAR T cell yield after continued expansion (d9), but not at an early time point (d4) (Fig. 4 
c). Importantly, neither pre-treatment with DNA-sensor inhibitors nor their combination with 
HDR enhancers significantly changed the CD4:CD8 ratio nor the T cell memory phenotype 
in comparison to mock-transfected T cells after 7 days of expansion (Suppl. Fig. 6 a, b).  
 
TRAC-replaced CAR T cells generated with virus-free method are functional in vitro and can 
be cryopreserved  
 
Finally, we performed functional in vitro characterization of CAR T cells generated with our 
optimized protocol using the combined transient DNA-sensor inhibition with HDR enhancer 
V1. We designed HDR templates to introduce a CD19-specific CAR with a long extracellular 
spacer (CD19.2) or a B cell maturation antigen (BCMA)-specific CAR47. CD19.2-/BCMA-
CAR T cells with CARs integrated into the TRAC locus were generated, expanded and 
cryopreserved at day 14.  In line with previous reports15, CD19.2-CAR T cells with CARs 
integrated in the TRAC locus displayed a lower basal CAR expression in comparison to lenti-
virally transduced CD19.2-CAR T cells (Suppl. Fig. 6). Similarly, site-specific insertion of a 
lentivirus-derived CD19.2-CAR overexpression cassette into the AAVS1 safe-harbor locus 
induced higher CAR expression levels than TRAC-insertion (Suppl. Fig. 6). Prior to 
cryopreservation, antigen-specific cytotoxicity of TRAC-integrated CAR T cells was 
evaluated using the VITAL assay48. T cells were co-cultured with fluorescently labeled target 
antigen-expressing tumor cells (Nalm-6: CD19+, BCMA-; MM.1S: BCMA+, CD19-) and 
target antigen-negative control tumor cells (CD19-KO Nalm-6) (Fig. 5 a). We observed 
antigen-specific and dose-dependent lysis of the respective target cells within the 4-hour 
assay highlighting intact effector function (Fig. 5 b, c). Cryopreservation after CAR T cell 
manufacturing is a standard procedure to allow for quality control assessments, facilitate 
safe shipment after centralized production and to accommodate the individual patient 
treatment schedule. CAR T cells must retain effector function after a freeze-and-thaw cycle, 
especially in the case of allogeneic off-the-shelf approaches. Therefore, we evaluated the 
cytokine profile of thawed CAR T cells with TRAC integration of CARs after polyclonal 
stimulation with PMA/Ionomycin or tumor cell challenge (Fig. 5 d, Suppl. Fig. 6 c, d). As 
expected, PMA/Ionomycin stimulation induced a high percentage of cytokine producers 
among CD4+ and CD8+ wildtype T cells as well as the respective TRAC-integrated CD19.2- 
or BCMA-CAR T cell conditions (Fig. 5 e-h). In contrast, co-culture with CD19+ Nalm-6 
tumor cells only induced cytokine production in CD19.2-CAR-positive CD4+ and CD8+ T cells 
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(Fig. 5 e-h). Similarly, co-culture with BCMA+ MM.1S cells induced cytokine production 
selectively in BCMA-CAR expressing T cells (Fig. 5 g, h). Jurkat cells, which neither express 
CD19 nor BCMA, did not elicit cytokine production by CAR-expressing T cells (Fig. 5 g, h). 
Overall, these results indicate that CAR T cells with CARs integrated into the TRAC locus 




Here, we show that the efficient manufacturing of TCR-replaced CAR T cells is possible 
using a virus-free technique. The baseline insertion rates of a 2015 bp CAR transgene 
exceed those of previously published virus-free approaches with similarly sized inserts. We 
show that two different pharmacological interventions synergistically improve both the 
relative knock-in rate and the absolute CAR T cell yield. This method may also be applicable 
to improve orthotopic TCR replacement29, repurposing endogenous transcriptional pathways 
as proposed by others25 or even pooled knock-in screens, such as PoKi-seq30.  
 
We have independently replicated findings by Nguyen et al. that the anionic nanoparticle 
PGA increases efficiency and decreases toxicity during electroporation of RNP and dsDNA 
HDRT, although the relative effects were smaller than originally reported32. Similarly, tCTS-
modified dsDNA HDRTs displayed an advantage over the regular HA configuration 
regarding knock-in efficiency, although overall CAR-T cell yield was only improved when the 
tCTS-modified HDRT was transfected in small amounts (0.5 µg). These differences may 
result from other changes in our protocols, such as the significant reduction of the co-
transfected RNP amount as well as the plate-bound stimulation22. The latter further reduces 
costs and may circumvent cell loss by bead depletion prior to transfection. 
 
Increased amounts of transfected dsDNA donors resulted in substantially reduced cell 
survival, coincided with increased secretion of IL-6, and TNFα and decreased overall CAR T 
cell yields. Combined DNA-sensor inhibition (ODN A151, RU.521) partially reduced IL-6 
release, but it did not affect TNFα secretion. In line with our initial hypotheses, these findings 
indicate that the toxicity of the virus-free approach is caused mainly by transfection of 
dsDNA donors, and is at least partially mediated via classical DNA sensing pathways. 
Independent of transfected DNA amount, our combined DNA-sensor inhibition reduced the 
release of Th2-associated cytokines such as IL-13 and IL-10, although the underlying 
mechanism remains to be elucidated. DNA-sensor inhibition provides a route towards further 
improvements of this method, potentially through inhibitors with higher potency or 
interference with additional (non-classical) DNA sensing pathways49 . 
 
Lowering the amount of transfected dsDNA donor may reduce toxicity by decreasing the 
physical strain imposed on the cell as well as provoking a weaker innate immune response. 
Whilst this is advantageous in terms of absolute CAR T cell yield, it also results in decreased 
relative HDR-rates. Thus, in order to increase CAR integration rates with low amounts of 
dsDNA donors, modulation of DNA repair towards HDR is desirable. Fortunately, multiple 
HDR enhancing drugs have been previously identified that are able to achieve this goal40,41. 
Our data show that two commercially available HDR enhancers increase relative knock-in 
rates in a dose-dependent manner. Intriguingly, suboptimal editing with a Cas12a derivative 
could be improved, which may be of interest for groups targeting AT-rich regions in the 
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genome50. Suboptimal editing with HiFi SpCas9 is likely caused by the intended mismatch in 
our TRAC sgRNA and the low amount of RNP used, as others can achieve highly efficient 
editing with this nuclease and rAAV621,43. 
 
We discovered that pre-electroporation DNA-sensor inhibition treatment increased relative 
knock-in rates of the CAR constructs. As HDR is cell cycle dependent38,51, the improved 
knock-in rates seen here may in part be attributed to a small increase in the proportion of T 
cells within S-phase at the time of transfection. Alternatively, this may be directly related to 
the use of the cGAS-inhibitor, RU.521. Recent studies reported that nuclear cGAS is a 
general inhibitor of DNA repair and prevents homology-directed DNA repair through direct 
condensation of genomic DNA52,53. In particular, this may explain the synergy between 
cGAS-directed DNA sensor inhibition and HDR enhancers observed in our experiments. 
Before clinical application, HDR enhancers and DNA-sensor inhibitors must be carefully 
evaluated regarding their effects on off-target gene editing, genomic DNA integrity and 
homology-independent dsDNA donor integration events. 
 
Along with the disclosed DNA sequences, the protocol is easily adaptable for preclinical 
investigations and after careful evaluation of safety, it may be scalable to suit clinical 
purposes in an allogeneic setting. It circumvents the need for the laborious, time consuming 
and costly manufacturing of viral vectors. By removing the practical hurdle of virus 
production, we hope our described technique may encourage groups to start working on 
CAR T cells, in particular TRAC-replaced CAR T cells. Our simplified technology platform 
could pave the way for the economical development of CAR T cell products and thus small 
scale CAR T cell trials. In doing so, we believe this platform may accelerate innovation for 
the treatment of various rare diseases as well as for solid tumour disease. 
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GUIDE-Seq54 for unbiased identification of CRISPR-Cas off-targets was performed as 
previously described43,55. Briefly, SpCas9-expressing HEK293 cells were co-transfected with 
dsDNA oligonucleotides (GUIDE-seq tag, for sequence see54) and either the original21 or 
target-sequence modified TRAC sgRNA (this study). Subsequently, genomic DNA was 
isolated after 72 hours using QuickExtract (Lucigen, USA) and fragmented using the 
LOTUS™ DNA library kit (IDT, Coralville, USA). Libraries were generated according to the 
original protocol54, followed by Illumina based next generation sequencing. Read alignment 
and data analysis was performed based on GUIDE-seq software54.  
PBMC isolation and T cell enrichment 
The study was performed in accordance with the declaration of Helsinki. Peripheral blood 
was obtained from healthy human adults after informed consent (Charité ethics committee 
approval EA4/091/19). Peripheral blood mononuclear cells (PBMC) were isolated using 
density-gradient centrifugation. Fresh heparinized whole blood was diluted 1:1 with sterile 
PBS (Gibco) and layered onto PANcoll separation medium (PAN Biotech) in 50 ml tubes 
(Falcon). Centrifugation was performed, with the brake function turned off, at 800 g for 20 
mins. Subsequently, the mononuclear cell layer was harvested and diluted in sterile PBS. 
After an initial centrifugation at 450 g for 10 minutes, supernatant was discarded. The pellet 
was resuspended in sterile PBS and centrifuged at 300 g for 10 minutes. Afterwards, the 
supernatant was discarded. PBMC pellets were resuspended in 10-20 ml PBS and counted 
using a Neubauer hemocytometer. Unless otherwise stated, PBMCs were positively 
enriched for CD3+ T cells using magnetic column enrichment with human CD3 microbeads 
according to the manufacturer’s recommendations (LS columns, Miltenyi).  
Cell culture 
PBMC or enriched T cells were cultured in RPMI 1640 (PAN Biotech), 10% heat-inactivated 
fetal calf serum (FCS) (Biochrom) and recombinant IL-2 (100 IU/ml), IL-7 (10 ng/ml) and IL-
15 (5 ng/ml). T cell stimulation was performed for 48 hours on anti-CD3/28 coated tissue 
culture plates unless stated otherwise. Coating of vacuum gas plasma treated polystyrene 
24-Well-Tissue-Culture plates (Corning Inc.) was performed overnight with 500 µl/well of 
sterile ddH2O supplemented with 1 µg/ml anti-CD3 mAb (clone OKT3, Invitrogen) and 1 
µg/ml anti-CD28 mAb (clone CD28.2, Biolegend).Plates were washed twice in PBS and 
once in RPMI without letting the wells dry out. T cells were seeded at a density of 1-1.5x 106 
per 24-well. For some experiments, stimulation was performed with Dynabeads Human T-
Activator CD3/CD28 beads (Invitrogen) according to the manufacturer’s protocol. Prior to 
nucleofection, beads were removed by incubation on strong magnet stands. The tumor cell 
lines Nalm-6 and MM.1S were obtained from the German Collection of Microorganisms and 
Cell Cultures GmbH (DSMZ) and cryopreserved for later use. The MM.1S cell line was 
genetically manipulated to overexpress GFP and firefly-luciferase (by A.R. and U.E.H.). All 
cell lines were freshly thawed and passaged 2-6 times prior to use in assays. Cell lines were 
cultured in RPMI1640 supplemented with 10% heat-inactivated FCS, 100 I.U./mL penicillin 
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and 100 µg/ml streptomycin. Tumor cell lines were split every 2-3  days. All cell culture was 
performed at 37°C and 5% CO2. 
Generation of dsDNA donor template for homology-directed insertion of a Chimeric Antigen 
Receptor 
Design of homology arms was performed as recently described28. Cloning of HDR donor 
templates with over 2000 bp insert size was performed with multiple fragment In-Fusion 
cloning according to the manufacturer’s protocol (Clontech, Takara). In brief, synthesis of 
400 bp dsDNA sequences homologous to the targeted locus were commissioned (gBlocks, 
IDT) with a total overlap of 16 bp with either the insert or the pUC19 vector backbone. 
Similarly, inserts consisting of a P2A self-cleaving peptide, CAR/reporter transgene and a 
bovine growth hormone-derived polyadenylation sequence were designed and synthesis 
was commissioned (gBlocks, IDT). As a model insert for a therapeutically relevant 
transgene, a CD19-specific chimeric antigen receptor was designed based on the original 
FMC63 scFv. We chose an intermediate length IgG1 hinge (for staining purposes) and a 
CD28 transmembrane and costimulatory domain linked to a cytosolic CD3 zeta domain. The 
CAR sequence was rationally designed and subsequently codon-optimized using two 
separate algorithms: first, using the COOL-algorithm56; in a second step, IDT’s codon 
optimization tool was used to eliminate any complexities and allow DNA synthesis. In-Fusion 
cloning strategies were planned with SnapGene (from Insightful Science; snapgene.com). 
For other experiments, CAR transgenes were PCR amplified (Kapa Hotstart HiFi 
Polymerase Readymix, Roche) from lenti-/retroviral expression plasmids with primers that 
allowed In-Fusion reaction with the existing donor template backbones (TRAC, AAVS1). The 
CD19.2-CAR with a long IgG1 spacer, CD28 transmembrane, CD28 co-stimulatory domain 
and CD3 zeta was originally designed and cloned by A. Künkele. The BCMA.4-1BB-zeta 
CAR was previously described47, and the plasmid was provided by A.R. and U.E.H. (MDC, 
Berlin). In-Fusion reactions were performed in 5 µl reactions at the recommended volume 
ratios. 1 µl of In-Fusion reaction mixtures were transformed into Stellar Competent E. coli in 
10 µl reactions and plated on ampicillin containing LB broth agar plates. After performing 
colony PCR for size validation with universal primers adjacent to the pUC19 insertion site 
(M13-for: 5’-GTAAAACGACGGCCAG-3’; M13-rev: 5’-CAGGAAACAGCTATGAC-3’), 3 - 5 
ml ampicillin-containing bacterial cultures of preferred clones were incubated at 37 °C 
overnight. Plasmids were purified using ZymoPURE Plasmid Mini Prep Kit (Zymo Research). 
Sequence validation of HDR donor template containing plasmids was performed by Sanger 
Sequencing (LGC Genomics, Berlin). HA-flanked transgenes were amplified from the 
plasmids by PCR using the KAPA HiFi HotStart 2x Readymix (Roche) with reaction volumes 
> 500 µl. PCR products were purified and concentrated using paramagnetic beads (AMPure 
XP, Beckman Coulter). This purification process included two washing steps in 70 % 
ethanol. Resulting HDRT concentrations were adjusted to 2 µg/µl in nuclease free water. For 
quantification, HDRTs were diluted 1:20 and measured on Nanodrop 1000 (Thermo Fisher). 
For optimal quantification accuracy, we recommend using Qubit fluorometer or similar.  
Electroporation buffer 
100 ml of electroporation buffer 1M were made according to the original publication37 by 
dissolving 37.3 mg KCl, 142.8 mg MgCl2 and 910 mg Mannitol in 40 ml sterile ddH2O 
(Ampuwa) prior to adding 60 ml of 0.2 M Phosphate Buffer Solution (Na2HPO4/NaH2PO4; pH 
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7.2). The buffer was sterile filtered using 0.2 µm syringe filters, aliquoted and stored at -
20°C. Prior to use it was thawed, shaken to dissolve intermittently formed precipitates and 
placed on ice.  
Formulation of ribonucleoproteins and mix with dsDNA templates 
Per transfection of 106 primary human T cells, 0.5 µl of an aqueous solution of 15–50 kDa 
poly(L-glutamic acid) (PGA, Sigma-Aldrich, 100 µg/µl) was mixed with 0.48 µl of synthetic 
modified sgRNA (2’-O-Methyl at 3 first and last bases, 3’ phosphorothioate bonds between 
first 3 and last 2 bases; Synthego, 3.2 µg/µl = 100 µM in TE Buffer; in some experiments 
modified sgRNA was provided by IDT) by pipetting thoroughly. 0.4 µl Recombinant 
Streptococcus pyogenes Cas9 protein (Alt-R S.p. Cas9 Nuclease V3, IDT, 10 µg/µl = 61 µM) 
was added and again mixed by thorough pipetting. The molar ratio of Cas9 and sgRNA was 
thus 1:2. The mixture was incubated for 15 minutes at room temperature (RT) to allow for 
RNP formation and placed on ice afterwards. For DNA-escalation studies, 0.25-2.0 µl of 
HDRT (stock concentration: 2 µg/µl) per 106 cells was added just prior to electroporation. For 
all other experiments, 0.5 µl HDRT per 106 cells was used. 
Electroporation 
Anti-CD3 and anti-CD28 stimulated primary human T cells were resuspended, pooled and 
washed twice in sterile PBS at 100 g for 10 minutes, RT. Afterwards, they were resuspended 
in 20 µl / 106 cells ice-cold electroporation buffer (1M, or P3 (Lonza) as indicated). The 
exposure time to the electroporation buffers was kept as short as possible. For 
electroporation of 1x 106 cells, 20 µl of resuspended cells were transferred to 1.88 µl of 
RNP/HDRT (except during DNA-escalation studies where different volumes were used) and 
mixed thoroughly. Afterwards, the T cell / RNP / HDRT mixture was transferred onto a 16-
well electroporation strip (20 µl = 106 cells per well, Lonza) or an electroporation cartridge 
(100 µl = 5x106 cells, Lonza). Cells were carefully transferred onto the electroporation strips 
using 200 µl tips to avoid trapping air in the solution. Electroporation strips and cartridges 
were tapped onto the bench several times to ensure correct placement of fluids within the 
electroporation vessel. Electroporation was performed on a 4D-Nucleofector™ Device 
(Lonza) using the program EH-115. Directly after electroporation, pre-warmed T cell medium 
was added onto the cells (90 µl per well and 450 µl per cartridge). Afterwards, resuspended 
cells were transferred to 96-well round bottom plates (50 µl / well) containing 150 µl pre-
warmed T cell medium per well (with or without HDR-enhancing supplements) at a density of 
0.5x 106 cells per well. For large scale CAR-T cell generation by electroporation in 
cartridges, 950 µl of pre-warmed T cell medium was used for initial resuspension, and cells 
were transferred into 24-well flat bottom plates (500 µl / well) containing 1.5 ml of T cell 
medium (with or without HDR-enhancing supplements) at a density of 2.5 x 106 cells per 
well.  
Lentivirus production and transduction 
Propagation of lentiviruses for CD19.2-CAR overexpression were prepared as previously 
described using transient transfection of 293T cells57. Briefly, the CD19.2 construct was 
cloned into the SIN epHIV7 lentiviral vector plasmid. Supernatant from transfected 293T 
cells was filtered and concentrated by ultra-centrifugation. Titers were determined by 
transduction of H9 cells with a dilution series of concentrated lentivirus from supernatants. 
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For T cell transduction, primary human T cells were enriched and plated on anti-CD3/CD28-
coated tissue culture plates in T cell medium. After two days, transduction was performed by 
centrifugation at 800 g for 30 minutes at 32°C with lentiviral supernatant (MOI of 1) 
supplemented with 1 mg/mL protamine sulfate (APP Pharmaceuticals, Barceloneta, Puerto 
Rico). Three days later, transduced T cells were sub-cultured in G-Rex10 devices (Wilson 
Wolf). 
CAR T cell expansion 
First medium change or first splitting of cells was performed 18 hours after electroporation 
unless stated otherwise. Cells were expanded in T cell medium on 96-well round bottom 
plates. During large scale CAR T cell generation for subsequent functional characterization, 
G-Rex10 devices (Wilson Wolf) were used for expansion. On day 14 after blood collection, 
cell products were frozen in FCS supplemented with 10% DMSO at a density of 107 cells / 
ml.  
Drug treatments before and after nucleofection 
To test the individual effects of selected DNA-sensor inhibitors, inhibitors were added to the 
T cells cultured in 24-well stimulation plates at the following concentrations 6-8 hours prior to 
electroporation: ODN A151 (Invivogen): 5 µM; RU.521 (Invivogen): 9.64 µM; H151 
(Invivogen): 3.58 µM; BX795 (Invivogen): 5 µM. The medium was mixed by pipetting and the 
resuspended T cells were incubated at 37°C and 5% CO2 until electroporation. 
Combined DNA-sensor inhibition: six hours prior to electroporation, 1 ml of the T cell 
medium per well (50 % of the medium) was removed from the 24-well stimulation plates and 
10 µl of the ODN A151 and 1 ul RU.521 was added to the remaining medium in the 
stimulation plate at the following concentrations: ODN A151: 5 µM; Ru.521: 4.82 µM. The 
medium was mixed by pipetting and the resuspended T cells were incubated at 37 °C and 5 
% CO2 until electroporation. 
To test the effects of HDR-enhancing substances (Alt-R HDR Enhancer (HDR-Enhancer 
version 1 [V1]), and HDR Enhancer version 2 [V2], both available at Integrated DNA 
Technologies) electroporated and resuspended T cells were transferred onto cell culture 
plates containing pre-warmed T cell medium with HDR-enhancing supplements in a volume 
ratio of 1:3 (50 µl cell suspension were added to 150 µl supplemented T cell medium). 
Concentrations tested ranged from 3.25 µM to 30 µM for HDR-Enhancer v1, and from 0.25 
µM to 2 µM for HDR-Enhancer v2. All concentrations stated in this publication refer to the 
supplemented T cell medium before seeding of T cells. 
Multiplex cytokine analysis of cell culture supernatants 
To characterize the cytokine response to transfected DNA, 100 µl of supernatant were 
harvested 24 hours after transfection. Supernatants were transferred to a sterile 96-Well-
Plate, sealed and stored at -80 °C until analysis. After thawing of supernatants, 
measurements were performed using the human Proinflammatory Panel 1 kit (for cytokines 
such as IL-1β, IL-6, IL-10, IL-13, TNFα) from Meso Scale Diagnostics according the 
manufacturer’s instructions. Analysis was performed at the Immunological Study Lab of 
CheckImmune GmbH on a Mesoscale Discovery platform. For each sample, the respective 
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value of the electrochemiluminescence (RFU-Signal) of the analyte concentration was 
calculated on the basis of a calibration curve and the blank control values were subtracted 
(fresh T cell medium). Measurements of the Meso Scale Diagnostics assay were performed 
and evaluated in accordance with the International Conference on Harmonisation Good 
Clinical Practice Guideline under ‘Validation of analytical procedures’. 
Flow cytometry 
Unless stated otherwise, flow cytometric assessments were carried out on a Cytoflex LX 
device (Beckman Coulter) using the 96-well plate format. Measurements of cell 
concentrations / cell counts were performed in 96-well flat-bottom cell culture plates, other 
measurements were performed in 96-well round-bottom cell culture plates. All staining 
panels are specified in Suppl. Table 2. Representative gating strategies for flow cytometry 
panels are depicted in Suppl. Fig. 7. Cell concentrations were assessed by acquiring 20 µl 
of resuspended cells diluted 1/10 in PBS without any prior washing steps.  
For detection of CAR-expression after knock-in, 40 µl of cell suspension was transferred 
onto the 96-U-Bottom-well plate and assessed following a series of successive washing and 
staining steps. For phenotyping, approximately 100,000 T cells were aliquoted per well. 
Each washing step included adding 240 µl PBS, centrifuging the plates at 400 g, 5 minutes, 
RT, discarding the supernatants and resuspending the pellets in the remaining volume by 
vortexing briefly. For any individual staining procedure, a mastermix of the antibodies / dyes 
diluted in PBS was prepared. 20 µl of the mastermix were added per well. The plates were 
vortexed briefly, incubated for 15 minutes at 4°C and briefly vortexed again. Because anti-Fc 
(anti-IgG1, Fcγ part) antibodies used to detect CAR protein can potentially bind to other 
detection antibodies, a first extracellular staining step with anti-Fc antibody only and a Live-
Dead discriminating dye, and subsequent washing step were performed prior to any other 
staining steps. The phenotype assessment presented in Suppl. Fig. 6 a, b was performed 
on a LSR-II Fortessa flow cytometer (BD Biosciences). The staining for this experiment was 
performed in 5 ml FACS tubes (Corning). Apart from this difference, it was carried out 
analogously to the other staining procedures. 
Cell cycle analysis 
Stimulation of CD3-enriched T cells as well as DNA-sensor inhibition treatment with RU.521 
and ODN A151 were performed as described above. For the staining, 200,000 cells were 
harvested, washed and stained with Live/Dead Fixable Blue (Invitrogen) for discrimination of 
dead cells. Then, cells were stained as described previously39. Briefly, the cells were fixed 
and permeabilized using the Intracellular Fixation & Permeabilization Buffer Set (Thermo 
Fisher, 88-8824). A mastermix containing 7AAD and KI67 Alexa Fluor 647 (Biolegend) was 
added to the cells for 30 minutes at 4 °C in the dark. After washing, cells were resuspended 
in PBS and run on the Cytoflex LX cytometer (Beckman Coulter). The 7AAD-dye stains DNA 
and indicates individual cell genomic DNA content to allow for differentiation of cells in 
resting (G0) and G1-phase vs. cells in S- and G2-phase. Ki-67 is an activation and 
proliferation marker which indicates cells outside resting phase (G0).  
VITAL assay to assess cytotoxicity 
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Effector T cells (TRAC-CD19.1-CAR T cells; TRAC-BCMA-CAR T cells and unedited 
(wildtype) T cells; each from the same 3 donors) were co-cultured with target cells 
expressing the surface protein recognized by the CAR, and control cells negative for this 
marker. For the CD19 VITAL assay, Nalm6 cells (CD19+, BCMA-) engineered to express 
Green Fluorescent Protein (GFP) served as target cells and CD19-Knock-Out Nalm6 cells 
engineered to express Red Fluorescent Protein (RFP) served as control cells. For the BCMA 
VITAL assay, MM.1S (CD19- BCMA+) engineered to express GFP served as target cells, 
while the same control cells were used. A 1:1 suspension of target and control cells was 
added to 25,000 (CAR) T cells in 96-well round bottom cell culture plates at 3 different 
effector : target : control cell ratios (1 : 2 : 2 , 1 : 1 : 1 and 1 : 0.2 : 0.2). The plates were 
centrifuged at 100 g, 3 min, RT, and then incubated at 37 °C, 5 % CO2 for 4 hours. 
Afterwards, the plates were centrifuged at 400 g, 10 min, RT, and the supernatant was 
discarded. Cell pellets were resuspended in PBS and the plates centrifuged again at 400 g, 
10 min, RT. The supernatant was discarded and the cells were stained with LIVE/DEADTM 
Fixable Blue Dead Cell Stain (Invitrogen, L23105) diluted 1:60 in 20 µl PBS per well for 10 
min at 4°C. Afterwards, 240 µl PBS / well were added and the plates were centrifuged at 400 
g, 15 minutes, RT.  The supernatant was discarded, the cells were resuspended in 50 µl 
PBS and analysed by flow cytometry. Effector cell mediated cytotoxicity was calculated from 
shifts in the target:control cell ratio relative to control conditions without effector cells. The 
experiment was performed on day 12 after blood collection (day 10 after electroporation).  
Intracellular cytokine analysis 
CAR T cells cryopreserved on day 14 after peripheral blood collection (day 12 after 
electroporation) were thawed by washing twice in pre-warmed RPMI1640 medium 
supplemented with 20% FCS and 10 ng/mL DNAse I (Roche, 11284932001). Thawed CAR 
T cells were rested in cytokine-free complete medium (RPMI1640 medium containing 10% 
FCS and 1% penicillin-streptomycin) overnight at 37 °C, 5 % CO2. Nalm6 and Jurkat cells 
were labelled with 2.5 μM Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE, 
ThermoFisher Scientific, V12883) and rested in complete medium overnight. 100,000 CAR T 
cells were co-cultured with CFSE-labelled Nalm6 or Jurkat cells (ratio 1:1) in 96-well round 
bottom plates for 6 hours. CAR T cells stimulated with 10 ng/mL PMA (Sigma Aldrich, 
P8139-1MG) and 2.5 μg/mL Ionomycin (Sigma Aldrich, I3909) were included as positive 
control for polyclonal stimulation independent of TCR expression, and CAR T cells cultured 
alone were included as negative control. Brefeldin A (Sigma Aldrich, B5936) was added at a 
concentration of 10 μg/mL after 1 hour of co-culture/stimulation. After 6 hours of stimulation, 
cells were harvested and stained with fixable blue dead cell stain dye. Subsequently, cells 
were fixed and permeabilized using the Intracellular Fixation & Permeabilization Buffer Set 
(Thermo Fisher, 88-8824). A first intracellular staining with anti-Fc AF647 was performed 
prior to washing twice with 1X permeabilization buffer. A second intracellular staining was 
performed with all other antibodies as stated in Suppl. Table 2.  
Data analysis, statistics and presentation 
Flow cytometry data was analysed with FlowJo software v10 (BD). Data from different 
assays was sorted in Excel (Microsoft). Graphs were created using Prism 9 (GraphPad). 
Conditions with failed electroporation (indicated by 4D-Nucleofector™ Device) were 
recorded during experiment and later excluded from analysis. Exploratory statistics were 
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performed with Prism 9 (Graphpad). Schemes and graphs in the presented Figures were 
created using an academic license of BioRender (www.biorender.com). 
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Figure 1: Low dosages of transfected dsDNA donor templates reduce toxicity during 
non-viral CAR T reprogramming  
Fig. 1: (a) Design of dsDNA donor templates for insertion of CAR transgenes into the TRAC locus. 
The transgene is comprised of a P2A self-cleavage site, the CAR encoding sequence followed by a 
STOP codon, and a bGH-derived poly-adenylation site (pA). Two template formats are used: the 
transgene flanked by regular homology arms (reg. HA, black) or homology arms with additional 
truncated Cas9 target sequences (tCTS-HA, red). (b) Experimental setup to evaluate co-transfection 
of RNPs and escalating doses of dsDNA donor templates with modified (tCTS-HA) and regular HA. (c, 
d) Representative flow cytometry plots show editing outcomes two days after co-transfection of RNP 
and escalating amounts of dsDNA donor templates of both HA formats. (e) Summary of flow 
cytometric analysis two days after transfection, n = 4 (two independent experiments). Black and red 
indicate the use of dsDNA HDRTs of regular HA or tCTS-HA format, respectively. Thick lines indicate 
mean values. Error bars indicate standard deviation. Lighter lines connect single data points from the 
same healthy donor over the different dsDNA amounts. Statistical analysis was performed using 
multiple Kruskal-Wallis tests with subsequent Dunn’s correction for multiple comparisons comparing 
values for each HDRT amounts with 0.5 µg HDRT as reference. (f) Illustration of common DNA-
sensing pathways of the innate immune system as well as cytokines produced downstream. (g) 
Summary of supernatant analysis 24 hours after transfection of dsDNA HDRT for IL-1β (lower limit of 
detection (LOD): 0.85 pg/ml), IL-6 (lower LOD: 0.13 pg/ml) and TNFα (lower LOD: 0.05 pg/ml), n=4 
(two independent experiments) Statistical analysis was performed using multiple Kruskal-Wallis tests 
with subsequent Dunn’s correction for multiple comparisons comparing cytokine concentrations for 
each HDRT amount with cytokine concentrations for electroporation without DNA. Asterisks represent 
different p-values calculated in the respective statistical tests (ns : p > 0.5;  * : p < 0.05; ** : p < 0.01; 
*** : p < 0.001). 
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Figure 2: DNA-sensor inhibition increases relative CAR insertion rate with minimal 
improvement of survival at optimized dsDNA donor dosage 
 
Fig. 2: (a) Illustration of common DNA-sensing pathways in immune cells that induce downstream 
cytokine production, as well as the presumed mode-of-action of different DNA sensor inhibitors used 
in subsequent experiments. (b) Experimental setup to evaluate transient DNA-sensor inhibition using 
four different compounds. Green: Drug is added 6 hours before transfection. Purple: Drug is 
supplemented into the medium for 48 hours after transfection. Blue: Drug is added 6 hours before 
transfection and supplemented into the medium for 48 hours after transfection. (c, d) Relative survival 
and CAR-detection rate after co-transfection of T cells with RNP and high amount of tCTS-modified 
HDR template (c) or optimized dose of HDR template with regular HA (d) Both figures show the effects 
of differently timed interventions with each drug compared to editing results with non-treated control 
cells. These are set to 100% and indicated by dotted lines, (n=3). (e) Experimental set up for the 
combined addition of TLR-9 inhibitor ODN A151 and the cGAS-inhibitor RU.521 with escalating 
amounts of dsDNA donor templates (as in Fig. 1b). DNA sensor inhibitors were supplemented 
together into the medium 6 hours prior to co-transfection of RNP and reg. HA dsDNA donor templates. 
(f) Summary of flow cytometric analysis two days after transfection. Data were obtained in parallel to 
controls presented in Fig.1 d-g from four healthy donors in two independent experiments. Editing 
outcomes of T cells that received combined DNA-sensor inhibition prior to electroporation are shown 
in orange. Black indicates the control values from Fig. 1 e. Thick lines indicate mean values, error bars 
indicate standard deviation. Light dots represent individual values. Light lines connect these for each 
donor. Descriptive statistical analysis was performed using paired, two-tailed Student’s t tests 
comparing values for no intervention with values for DNA-Sensor inhibition. (g) Summary of 
supernatant analysis 24 hours after transfection for cytokines associated with DNA-sensing such as 
IL-1β (lower LOD: 0.85 pg/ml), IL-6 (lower LOD: 0.13 pg/ml) and TNFα (lower LOD: 0.05 pg/ml) as 
well as the Th2-associated cytokines IL-10 (lower LOD: 0.01 pg/ml) and IL-13 (lower LOD: 0.27 pg/ml) 
Descriptive statistical analysis was performed using paired, two-tailed Student’s t tests comparing 
cytokine concentrations for no intervention with cytokine concentrations for DNA-Sensor inhibition. 
Asterisks represent different p-values calculated in the respective statistical tests (ns : p > 0.5;  * : p < 
0.05; ** : p < 0.01; *** : p < 0.001). 
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Figure 3: HDR enhancing compounds improve CAR integration 
rates in primary human T cells 
 
Fig. 3: (a) Experimental setup to identify the effects of HDR enhancing substances on TRAC-
integration of CAR transgenes. (b) Representative flow cytometry plots comparing the effects of HDR 
enhancer V1 or V2, supplemented at different concentrations, on editing outcomes. (c) Summary of b 
with data from nine biological replicates in three independent experiments, two and seven days after 
transfection. The thick line indicates mean values. Light grey lines connect single data points, shown 
as light grey dots, from each biological replicate across the different conditions. Range of y-axes 
differs for CAR T cell count of d4 and d9. (d) Scheme illustrating two dsDNA donor templates of 
regular HA format for integration of CARs at two distinct sites of the TRAC locus, showing the three 
different Cas nuclease enzymes pre-complexed with different guide RNA to allow optimal targeting for 
each TRAC dsDNA donor template (=total of six distinct RNPs). (e) Representative flow cytometry 
plots and summary of results showing the effect of HDR enhancer V1 (15 µM) on CAR integration 
rates seven days after transfection with six different RNP / HDR template combinations as outlined in 
d. Statistical analysis was performed for RNP/HDRT combinations 1 and 2 using paired, two-tailed 
Student’s t tests comparing values for no intervention with values for HDR-Enhancer v1 (15 µM). (f). 
Test of Alt-R HiFi SpCas9 V3 Cas9 in an experimental setup analogous to a-c with a graphical 
representation as in c. A sketch of the RNP relates to d. Again, range of y-axes differs for CAR T cell 
count of d4 and d9. Data were obtained simultaneously from four biological replicates in one 
experiment. Asterisks represent different p-values calculated in the respective statistical tests (ns : p > 
0.5;  * : p < 0.05; ** : p < 0.01; *** : p < 0.001). 
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Figure 4: Synergy of DNA-sensor inhibition and HDR enhancers 
improves efficiency and yield of TRAC-replaced CAR T cell 
generation 
 
Fig. 4: (a) Experimental setup adding the combination of DNA-sensor inhibition and HDR-
enhancement as an additional dimension to the setup originally presented in Fig. 1 e and Fig. 2 f. 
DNA-sensor inhibition was performed 6 hours prior to electroporation with the compounds ODN A151 
and RU.521. After transfection, cells were cultured in HDR enhancer V1 supplemented medium (15 
µM) for 16 hours. (b) Summary of relative CAR integration rates and CAR T cell counts two and seven 
days after transfection. 0.5 µg and 1.0 µg of dsDNA donor templates of both formats (reg. HA, black; 
and tCTS-HA, red) were used. Data were obtained in parallel to controls presented in Fig 1 d+e from 
four biological replicates. Furthermore, data from one additional experiment with two biological 
replicates only analyzed on d 9 were also included, mean +/- standard deviation. Statistical analysis 
was performed using paired, two-tailed student‘s t test comparing values for no intervention (“none”) 
with values for a combined pharmacological intervention (“both”), individually for reg. HA and tCTS-
HA. (c) Summary of CAR integration rates and CAR T cell yield comparing T cells with DNA-sensor 
inhibition (orange) or without it (black) prior to transfection of RNP with 1.0 µg reg. HA HDRT when 
cultured in medium supplemented with different dosages of the two HDR enhancers. Range of y-axes 
differs for CAR T cell count of d 4 and d 9. Data were obtained from three biological replicates in two 
independent experiments. Asterisks represent different p-values calculated in the respective statistical 
tests (ns : p > 0.5;  * : p < 0.05; ** : p < 0.01; *** : p < 0.001). 
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Figure 5: Functional characterization of TRAC-integrated CD19- and 
BCMA-specific CAR T cells in vitro 
 
Fig. 5: (a) Experimental setup of a flow cytometric VITAL assay. (b) Representative flow cytometry 
plots showing live target and control tumors cells after 4 hour VITAL cytotoxicity assays, shown for the 
highest effector (E):target (T):control (C) cell ratio tested (1 : 0.2 : 0.2). Either Nalm-6 cells (CD19+ 
BCMA-; top) or MM.1S cells (CD19-, BCMA+; bottom) were used as the target cell population. CD19 
knock-out Nalm-6 cells served as controls in both cases. (c) Summary of VITAL assays performed 
simultaneously with edited cells from three healthy donors in three different E : T : C ratios, (n=3). (d) 
Experimental setup for detection of intracellular cytokines after different stimulations. (e,f) 
Representative flow cytometry plots of CD4+ (e) or CD8+ (f) CD19.2-CAR+ T cells after polyclonal 
stimulation (PMA/Ionomycin) or co-culture with either CD19+ Nalm-6 cells or CD19- Jurkat cells. 
Representative gating strategy included in Suppl. Fig. 7. (g, h) Summary of e and f. Stimulations were 
performed in two technical replicates each. Data were obtained from three biological replicates of 
wildtype T cells, two biological replicates of TRAC-integrated CD19.2-CAR T cells and one biological 
replicate of TRAC-integrated BCMA-CAR T cells, each assessed in technical duplicates. Boolean 
gating was used to identify cells that produced one, two or three of the following cytokines: IFN-γ, IL-2 
and TNFα. Error bars show standard deviation. 
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